Jamey Marth

Jamey Marth, Ph.D.

A holistic and rigorous integration of multiple disciplines is required to perceive and most effectively manipulate the cellular mechanisms of health and disease. The Sanford-Burnham Medical Research Institute facilitates this by supporting the frontiers of biomedical research, the future of interdisciplinary expertise, and the development of more effective therapeutics.

  • Carbon Chair of Biochemistry and Molecular Biology, UCSB
    Mellichamp Chair of Systems Biology, UCSB
  • Research

    Developing and applying interdisciplinary approaches in cell biology and biomedical research to discover disease origins and mechanisms.

  • Biography

    Dr. Marth is Professor and Director of the UC Santa Barbara Center for Nanomedicine, and of the Sanford-Burnham Medical Research Institute.



View All Publications

Jamey Marth's Research Focus

Sepsis, Diabetes - General, Inflammatory/Autoimmune Disease, Coagulopathy, Cancer

The Marth laboratory develops and applies biomedical research technologies to discover the origins and mechanisms of disease syndromes including diabetes, autoimmunity, inflammation, coagulopathy, cancer, and sepsis. Significant progress is made by research that integrates the four main families of cellular organic molecules including the nucleic acids, proteins, lipids, and glycans. Past achievements included the development of Cre-loxP conditional mutagenesis, a technique essential to interrogate cell type-specific gene function in health and disease. The laboratory further pioneered the application of transgenesis and gene-targeting technologies to discover the functions of protein glycosylation in cells and tissues of living mammals. Like protein phosphorylation, glycosylation is a metabolic process that alters protein structure and function. The Marth laboratory discovered that changes in cellular protein glycosylation are among the metabolic origins of diseases and syndromes including diabetes and sepsis, and can further explain the onset of chronic inflammatory states that develop into more severe disorders associated with tissue degeneration and autoimmunity. Cancer is another common grievous disease wherein significant metabolic signposts exist that include altered protein glycosylation on the cell surface. Such highly expressed tumor antigens that combine glycan and protein sequences in unique combinations are predicted to enable more selective drug delivery at high efficiency to further improve upon cancer treatment by nanomedicine. The biological applications of nanotechnologies to identify template-independent and acquired metabolic factors is becoming essential to detect and intervene in the onset and progression of common non-genetic diseases. In ongoing research, the laboratory continues to collaborate with bioengineers and clinicians to develop integrative diagnostics that combine genetic and metabolic factors causing cellular dysfunction-which is the definition of all disease. The laboratory’s discoveries of disease origins and mechanisms have provided the rationale for planned and ongoing therapeutic development efforts to generate and test in clinical trials novel drugs to treat inflammation, autoimmunity, cancer, diabetes, and sepsis.

About Jamey Marth


Jamey Marth is Professor and Director of the University of California Santa Barbara Center for Nanomedicine, and of the Sanford-Burnham Medical Research Institute. He is also a Professor in the UCSB Department of Molecular, Cellular and Developmental Biology, and in the UCSB Biomolecular Science and Engineering program. Dr. Marth is the inaugural recipient of the UCSB Carbon Endowed Chair of Biochemistry and Molecular Biology and a recipient of the UCSB Mellichamp Endowed Chair of Systems Biology. Dr. Marth received a Ph.D. degree in Pharmacology from the University of Washington where he trained in the laboratories of Roger M. Perlmutter, current Executive Vice-President of Merck, and the late Edwin G. Krebs, a 1992 Nobel Prize laureate. Dr. Marth was recruited to UC San Diego in 1995 by George Palade - a 1974 Nobel Prize laureate, where he was appointed as an Investigator of the Howard Hughes Medical Institute and Professor in the Department of Cellular and Molecular Medicine, prior to his current positions.

Become a Partner / Donate
Your support is crucial in turning hope into healing. Your support is crucial in turning hope into healing. Learn More
Social Media
Related to My Areas of Research

Ph.D., University of Washington, Pharmacology, 1987
B.S., University of Oregon, Genetics and Chemistry, 1984

Other Appointments

Director, UCSB Center for Nanomedicine
Professor, UCSB Department of Molecular, Cellular and Developmental Biology
Professor UCSB Biomolecular Sciences and Engineering

Funding Awards and Collaborative Grants

Howard Hughes Medical Institute Investigator award, 1995-2009
Hearst Foundations, 2011-2013

Honors and Recognition

John Carbon Chair in Biochemistry and Molecular Biology, 2009 - Pres.
Duncan and Suzanne Mellichamp Chair in Systems Biology, 2009 - Pres.
Investigator, Howard Hughes Medical Institute, 1995 - 2009
University of California San Diego, Professor, 1999 - 2009
Faculty Scholarship, The Medical Research Council of Canada, 1991 - 1995

Sign In Skip Navigation Links Skip navigation links
Our Mission
Training & Education
Our Supporters
Privacy Policy